Moderna, Inc. recently revealed that the company is actively planning its future product pipeline, and it is expected that as many as three new vaccine products may be launched between 2027 and 2028.

Evogene will hold a special general meeting of shareholders in Rehovot, Israel on Nov. 10, 2026. Shareholders will vote on electing Oz Adler and Dr. Adi Zuloff-Shani to the board. Ballots will also cover the election of Itay Maroz and Shahar Zadok, subject to approval of a cooperation agreement. The meeting will also vote on a cooperation agreement between Evogene and L.I.A. Pure Capital and Invest-Pro Shukai Hon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004722), on October 06, 2026, and is solely responsible for the information contained therein.

02:57 PM EDT, 10/06/2026 (MT Newswires) -- Simulations Plus (SLP) said Tuesday that affiliates of Altaris have completed the acquisition of the company. The transaction price was $375 million, with each Simulations shareholder receiving $18.50 in cash per share, according to an earlier statement. As a result of the acquisition, Simulations said it has become a privately held company and its common stock will no longer trade on the Nasdaq Global Select Market.